Durvalumab & SCLC: Survival Boost, But Is It Worth the Cost?
A significant, yet predictably complex, victory has emerged in the fight against small cell lung cancer (SCLC). New data from the ADRIATIC trial demonstrates that durvalumab, an immunotherapy drug, substantially extends both overall and progression-free survival for patients with limited-stage SCLC. However, this clinical triumph is immediately shadowed by a familiar challenge in oncology: astronomical … Read more